{"filing":{"accession_number":"0001193125-26-265841","cik":"0002012593","ticker":"RAPP","company_name":"Rapport Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"rapp-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526265841/rapp-20260610.htm"},"events":[{"id":5653,"run_id":4956,"accession_number":"0001193125-26-265841","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Rapport Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class II directors (James Healy, Robert J. Perez, and Raymond Sanchez) and (ii) ratification of PwC as the independent auditor. The detailed vote tallies (For/Withheld/Broker Non-Votes for directors; For/Against/Abstain for auditor ratification) are the core content of Item 5.07, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.","company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5851,"accession_number":"0001193125-26-265841","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Rapport Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class II directors (James Healy, Robert J. Perez, and Raymond Sanchez) and (ii) ratification of PwC as the independent auditor. The detailed vote tallies (For/Withheld/Broker Non-Votes for directors; For/Against/Abstain for auditor ratification) are the core content of Item 5.07, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:13:15.315680+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5851,"accession_number":"0001193125-26-265841","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Rapport Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class II directors (James Healy, Robert J. Perez, and Raymond Sanchez) and (ii) ratification of PwC as the independent auditor. The detailed vote tallies (For/Withheld/Broker Non-Votes for directors; For/Against/Abstain for auditor ratification) are the core content of Item 5.07, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:13:15.315680+00:00","company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","filing_date":"2026-06-10"}]}